Post-marketing Surveillance of the Safety and Effectiveness of Rosiglitazone/Metformin in Korean Patients with Type 2 Diabetes.
10.12793/jkscpt.2012.20.2.195
- Author:
Hankyu LEE
1
;
So Hyun PARK
;
Shin Young OH
;
Yil Seob LEE
Author Information
1. Glaxo SmithKline Korea, Seoul, Korea. Yil.S.Lee@gsk.com
- Publication Type:Original Article
- Keywords:
Rosiglitazone;
Metformin;
Post-marketing surveillance
- MeSH:
Blood Glucose;
Chest Pain;
Fasting;
Gastritis;
Glucose;
Hemoglobins;
Humans;
Incidence;
Metformin;
Pneumonia, Bacterial;
Thiazolidinediones
- From:Journal of Korean Society for Clinical Pharmacology and Therapeutics
2012;20(2):195-204
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: To evaluate the safety and effectiveness of rosiglitazone/metformin in patients with type 2 (non-insulin-dependent) diabetes. METHODS: A total of 982 patients were enrolled by 19 physicians from November 2003 to November 2010. Patients treated with rosiglitazone/metformin at least once, were included in safety assessment. The incidences of adverse events (AEs) and serious adverse events (SAEs) were estimated. The effectiveness of rosiglitazone/metformin was evaluated through change in fasting blood glucose (FBG), 2-hour postprandial glucose (2hr PPG), Hemoglobin A1c (HbA1c). RESULTS: Of the 982 patients, 713 patients with the mean age of 56.4 +/- 11.5 years were included in the safety assessment. A total of 130 AEs were reported from 110 patients (15.4 %). The most frequent AEs were upper respiratory infection (2.4 %), oedema (2.2 %), gastritis (1.3 %), and weight increase (1.1 %). The incidence of unexpected AEs was 5.9 % (42/713, 47 AEs). Three SAEs such as bacterial pneumonia, hyperglycaemia, chest pain were reported in 2 patients. As it is about effectiveness, patients showed statistically significant reductions after treatment of rosiglitazone/metformin in FBG, 2hr PPG, and HbA1c (P<0.001 by paired t-test, for all). CONCLUSION: Our data suggest that rosiglitazone/metformin is well tolerated and effective in Korean patients with type 2 (non-insulin-dependent) diabetes.
